ArticleAnimal models and experimental medicine2026
Metformin enhances external urethral sphincter integrity and restores continence via AMPK activation in a rat model of stress urinary incontinence.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundStress urinary incontinence (SUI) is primarily caused by structural and functional damage to the external urethral sphincter (EUS). In previous studies, metformin, a known AMP-activated protein kinase (AMPK) activator, has shown repair effects after skeletal muscle injury. This study explored its therapeutic effect and molecular mechanisms in SUI associated with EUS injury.
methodsThe SUI model was established by double vaginal dilation. Rats were assigned to sham, vehicle-treated, or metformin-treated (200 mg/kg/day, oral) groups. Urodynamic testing was performed after 7 and 14 days. Subsequently, EUS tissues were isolated for histological (hematoxylin and eosin [H&E], Masson's), apoptotic (TUNEL), ultrastructural (transmission electron microscopy [TEM]), and molecular analyses. Finally, C2C12 myotubes cells were treated with varying concentrations of metformin to evaluate the expression of phosphorylated AMPK (p-AMPK) and MYH1/2, which are markers of skeletal muscle fiber type and regeneration.
resultsAbdominal leak point pressure (ALPP) and bladder leak point pressure (BLPP) decreased after double vaginal dilation, suggesting that SUI was established. After treatment for 7 and 14 days, respectively, metformin significantly increased ALPP and BLPP (p < 0.05) without affecting maximum bladder capacity (p > 0.05). Masson's staining and TEM revealed that metformin improved disorganized EUS architecture. Further, Western blot analysis demonstrated that metformin increased the expression of MYH1/2 and p-AMPK in vivo and in vitro. Meanwhile TUNEL assay showed that metformin treatment reduced apoptotic cells in the EUS from SUI rats.
conclusionsThese results indicate that metformin enhances EUS repair to improve SUI via activating the AMPK signaling pathway. These findings provide new insights into therapeutic strategies for SUI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.